Richard B. Gaynor's most recent trade in Zai Lab Limited - ADR was a trade of 2,500 American Depositary Shares done at an average price of $19.5 . Disclosure was reported to the exchange on Sept. 3, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zai Lab Ltd (ADR) | Richard B. Gaynor | Director | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 03 Sep 2024 | 2,500 | 46,568 (0%) | 0% | 19.5 | 48,750 | American Depositary Shares |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 26,460 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 24,995 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Zai Lab Ltd (ADR) | Richard B. Gaynor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 21,253 | 49,068 (0%) | 0% | 0 | American Depositary Shares | |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 1,236 | 63,036 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 256 | 13,079 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 230 | 11,739 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 224 | 11,424 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 31 May 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 21,786 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 07 Jul 2023 | 5,957 | 0 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.88 per share. | 07 Jul 2023 | 1,430 | 20,356 (0%) | 0% | 29.9 | 42,728 | Ordinary Shares |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 29 Jun 2023 | 12,732 | 12,732 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 29 Jun 2023 | 5,985 | 5,985 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 07 Jul 2022 | 11,554 | 11,554 | - | - | Non Qualified Stock Option (Right to Buy) | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 07 Jul 2022 | 5,957 | 5,957 | - | - | Restricted Stock Unit Award | ||
| Infinity Pharmaceuticals Inc | Richard B. Gaynor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 45,000 | 45,000 | - | - | Stock Option(right to buy) | |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 16,524 (0%) | 0% | - | Ordinary Shares | |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | 14 Jun 2022 | 7,585 | 0 | - | - | Restricted Stock Unit Award | ||
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.19 per share. | 14 Jun 2022 | 695 | 15,829 (0%) | 0% | 27.2 | 18,897 | Ordinary Shares |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2021 | 5,578 | 10,278 (0%) | 0% | - | - | |
| Alkermes PLC | Dr. Richard B. Gaynor, M.D. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.11 per share. | 02 Dec 2021 | 1,339 | 8,939 (0%) | 0% | 22.1 | 29,605 | - |